Australia's largest stock trading and investment forum Australia's #1 stock forum

CHM

0.00%

1.4¢ chimeric therapeutics limited

about $28 for 12B - just try to get your head around that w/o...

First 338 Last

Share
Profile

Follow
bavarian1975

3,116 Posts.

1592

23/07/22

17:07

Post #: 62691484
Share

Originally posted by Specyray: ↑

Future price target for CHM.
11.9 BILLION US.
Now does that seem to far fetched ?
I would not think so. You see it was not me that put that price target on CHM, but someone very important. Let me explain.
Kite Pharma was bought by Gilead in 2017 for US$11.9 Billion and Celgene was purchased for US$74 Billion.
Celgene had a variety of products in development, a bit like CHM but much more further advanced.
Kite Pharma was focussed on a CAR T Cell therapy with its Yescarta product being the first therapy of this kind approved by the FDA.
So both Kite and Celgene had some amazing management and development team to get these products approved from scratch to FDA approval, and guess where most of them are now. Yep, right here with CHM. This team was involved with 4 of the first 5 CAR Ts to be approved by the FDA.
Jennifer mentioned on her visit to Melbourne and Sydney this year that she and her team were building another Celgene, and that's 74 billion us.
I only put up Kite Pharma price as it would be the first step to getting some of CHM products to the end of a Phase two trails.
Now what would CHM share price be if our market cap was US$ 11.9 b, can someone work that out.
And how much would the share price be if we had a market cap of US$ 74b, can someone work that out.
These figures would be years from now, but it could possibly happen with this crack team at CHM. This is Jennifer's vision.

Expand

about $28 for 12B - just try to get your head around that w/o worrying bout the other number. Not counting dilution etc

CHM Price at posting: 12.5¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 43 more messages in this thread...

First 338 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

about $28 for 12B - just try to get your head around that w/o...

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News

about $28 for 12B - just try to get your head around that w/o...

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Featured News